Intrinsic value of Qiagen - QGEN

Previous Close

$34.51

  Intrinsic Value

$28.11

stock screener

  Rating & Target

hold

-19%

Previous close

$34.51

 
Intrinsic value

$28.11

 
Up/down potential

-19%

 
Rating

hold

We calculate the intrinsic value of QGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 7.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  6.00
  5.90
  5.81
  5.73
  5.66
  5.59
  5.53
  5.48
  5.43
  5.39
  5.35
  5.31
  5.28
  5.25
  5.23
  5.21
  5.19
  5.17
  5.15
  5.14
  5.12
  5.11
  5.10
  5.09
  5.08
  5.07
  5.06
  5.06
  5.05
  5.05
Revenue, $m
  1,503
  1,591
  1,684
  1,780
  1,881
  1,986
  2,096
  2,211
  2,331
  2,456
  2,588
  2,725
  2,869
  3,020
  3,178
  3,343
  3,517
  3,698
  3,889
  4,088
  4,298
  4,517
  4,748
  4,989
  5,243
  5,509
  5,788
  6,080
  6,388
  6,710
Variable operating expenses, $m
  454
  466
  478
  491
  505
  519
  534
  549
  565
  582
  349
  367
  387
  407
  428
  451
  474
  498
  524
  551
  579
  609
  640
  672
  707
  742
  780
  819
  861
  904
Fixed operating expenses, $m
  858
  877
  897
  916
  937
  957
  978
  1,000
  1,022
  1,044
  1,067
  1,091
  1,115
  1,139
  1,164
  1,190
  1,216
  1,243
  1,270
  1,298
  1,327
  1,356
  1,386
  1,416
  1,447
  1,479
  1,512
  1,545
  1,579
  1,614
Total operating expenses, $m
  1,312
  1,343
  1,375
  1,407
  1,442
  1,476
  1,512
  1,549
  1,587
  1,626
  1,416
  1,458
  1,502
  1,546
  1,592
  1,641
  1,690
  1,741
  1,794
  1,849
  1,906
  1,965
  2,026
  2,088
  2,154
  2,221
  2,292
  2,364
  2,440
  2,518
Operating income, $m
  190
  248
  309
  373
  440
  510
  584
  662
  744
  830
  1,172
  1,267
  1,368
  1,474
  1,585
  1,703
  1,827
  1,957
  2,094
  2,239
  2,392
  2,553
  2,722
  2,901
  3,089
  3,287
  3,496
  3,716
  3,948
  4,192
EBITDA, $m
  574
  640
  709
  781
  857
  936
  1,020
  1,108
  1,201
  1,298
  1,400
  1,508
  1,621
  1,740
  1,866
  1,998
  2,137
  2,283
  2,438
  2,600
  2,771
  2,951
  3,141
  3,341
  3,552
  3,773
  4,007
  4,253
  4,511
  4,784
Interest expense (income), $m
  18
  95
  103
  112
  120
  130
  139
  149
  160
  171
  182
  194
  207
  220
  233
  248
  263
  279
  295
  312
  330
  349
  369
  390
  412
  435
  459
  485
  511
  539
  568
Earnings before tax, $m
  95
  145
  197
  252
  310
  371
  435
  502
  573
  648
  978
  1,061
  1,148
  1,240
  1,338
  1,440
  1,548
  1,662
  1,782
  1,909
  2,042
  2,183
  2,332
  2,488
  2,654
  2,828
  3,011
  3,205
  3,409
  3,623
Tax expense, $m
  26
  39
  53
  68
  84
  100
  117
  136
  155
  175
  264
  286
  310
  335
  361
  389
  418
  449
  481
  515
  551
  589
  630
  672
  716
  763
  813
  865
  920
  978
Net income, $m
  70
  106
  144
  184
  226
  271
  317
  366
  418
  473
  714
  774
  838
  905
  976
  1,051
  1,130
  1,213
  1,301
  1,393
  1,491
  1,594
  1,702
  1,817
  1,937
  2,064
  2,198
  2,339
  2,488
  2,645

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,609
  4,881
  5,165
  5,461
  5,769
  6,092
  6,429
  6,781
  7,149
  7,535
  7,938
  8,359
  8,801
  9,263
  9,748
  10,255
  10,787
  11,344
  11,929
  12,541
  13,183
  13,857
  14,563
  15,305
  16,082
  16,898
  17,753
  18,651
  19,594
  20,583
Adjusted assets (=assets-cash), $m
  4,609
  4,881
  5,165
  5,461
  5,769
  6,092
  6,429
  6,781
  7,149
  7,535
  7,938
  8,359
  8,801
  9,263
  9,748
  10,255
  10,787
  11,344
  11,929
  12,541
  13,183
  13,857
  14,563
  15,305
  16,082
  16,898
  17,753
  18,651
  19,594
  20,583
Revenue / Adjusted assets
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
  0.326
Average production assets, $m
  1,817
  1,924
  2,036
  2,152
  2,274
  2,401
  2,534
  2,673
  2,818
  2,970
  3,128
  3,295
  3,469
  3,651
  3,842
  4,042
  4,251
  4,471
  4,701
  4,943
  5,196
  5,461
  5,740
  6,032
  6,338
  6,660
  6,997
  7,351
  7,723
  8,112
Working capital, $m
  325
  344
  364
  385
  406
  429
  453
  478
  503
  531
  559
  589
  620
  652
  686
  722
  760
  799
  840
  883
  928
  976
  1,025
  1,078
  1,132
  1,190
  1,250
  1,313
  1,380
  1,449
Total debt, $m
  1,911
  2,067
  2,230
  2,401
  2,578
  2,764
  2,957
  3,160
  3,372
  3,593
  3,825
  4,067
  4,321
  4,587
  4,866
  5,157
  5,463
  5,784
  6,120
  6,472
  6,841
  7,228
  7,635
  8,061
  8,508
  8,977
  9,469
  9,985
  10,527
  11,096
Total liabilities, $m
  2,650
  2,807
  2,970
  3,140
  3,317
  3,503
  3,697
  3,899
  4,111
  4,332
  4,564
  4,807
  5,061
  5,326
  5,605
  5,897
  6,202
  6,523
  6,859
  7,211
  7,580
  7,968
  8,374
  8,800
  9,247
  9,716
  10,208
  10,725
  11,266
  11,835
Total equity, $m
  1,959
  2,074
  2,195
  2,321
  2,452
  2,589
  2,732
  2,882
  3,038
  3,202
  3,373
  3,553
  3,740
  3,937
  4,143
  4,358
  4,584
  4,821
  5,070
  5,330
  5,603
  5,889
  6,189
  6,504
  6,835
  7,181
  7,545
  7,927
  8,327
  8,748
Total liabilities and equity, $m
  4,609
  4,881
  5,165
  5,461
  5,769
  6,092
  6,429
  6,781
  7,149
  7,534
  7,937
  8,360
  8,801
  9,263
  9,748
  10,255
  10,786
  11,344
  11,929
  12,541
  13,183
  13,857
  14,563
  15,304
  16,082
  16,897
  17,753
  18,652
  19,593
  20,583
Debt-to-equity ratio
  0.980
  1.000
  1.020
  1.030
  1.050
  1.070
  1.080
  1.100
  1.110
  1.120
  1.130
  1.140
  1.160
  1.170
  1.170
  1.180
  1.190
  1.200
  1.210
  1.210
  1.220
  1.230
  1.230
  1.240
  1.240
  1.250
  1.250
  1.260
  1.260
  1.270
Adjusted equity ratio
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425
  0.425

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  70
  106
  144
  184
  226
  271
  317
  366
  418
  473
  714
  774
  838
  905
  976
  1,051
  1,130
  1,213
  1,301
  1,393
  1,491
  1,594
  1,702
  1,817
  1,937
  2,064
  2,198
  2,339
  2,488
  2,645
Depreciation, amort., depletion, $m
  384
  392
  400
  408
  417
  426
  436
  446
  457
  468
  228
  240
  253
  266
  280
  295
  310
  326
  343
  361
  379
  399
  419
  440
  463
  486
  511
  537
  564
  592
Funds from operations, $m
  453
  497
  544
  592
  643
  697
  754
  813
  875
  941
  942
  1,015
  1,091
  1,172
  1,257
  1,346
  1,440
  1,540
  1,644
  1,754
  1,870
  1,992
  2,121
  2,257
  2,400
  2,550
  2,709
  2,876
  3,052
  3,237
Change in working capital, $m
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  30
  31
  33
  34
  36
  37
  39
  41
  43
  45
  47
  50
  52
  55
  57
  60
  63
  66
  70
Cash from operations, $m
  435
  478
  524
  572
  622
  674
  730
  788
  849
  914
  914
  985
  1,060
  1,139
  1,223
  1,311
  1,403
  1,500
  1,603
  1,711
  1,825
  1,945
  2,071
  2,205
  2,345
  2,493
  2,649
  2,813
  2,986
  3,168
Maintenance CAPEX, $m
  -125
  -133
  -140
  -149
  -157
  -166
  -175
  -185
  -195
  -206
  -217
  -228
  -240
  -253
  -266
  -280
  -295
  -310
  -326
  -343
  -361
  -379
  -399
  -419
  -440
  -463
  -486
  -511
  -537
  -564
New CAPEX, $m
  -102
  -107
  -112
  -117
  -122
  -127
  -133
  -139
  -145
  -152
  -159
  -166
  -174
  -182
  -191
  -200
  -210
  -220
  -230
  -241
  -253
  -265
  -278
  -292
  -306
  -321
  -337
  -354
  -371
  -390
Cash from investing activities, $m
  -227
  -240
  -252
  -266
  -279
  -293
  -308
  -324
  -340
  -358
  -376
  -394
  -414
  -435
  -457
  -480
  -505
  -530
  -556
  -584
  -614
  -644
  -677
  -711
  -746
  -784
  -823
  -865
  -908
  -954
Free cash flow, $m
  208
  239
  272
  306
  343
  381
  422
  464
  509
  556
  538
  590
  646
  704
  765
  830
  898
  970
  1,046
  1,127
  1,211
  1,300
  1,394
  1,494
  1,598
  1,709
  1,825
  1,948
  2,078
  2,214
Issuance/(repayment) of debt, $m
  153
  156
  163
  170
  178
  185
  194
  203
  212
  221
  232
  243
  254
  266
  279
  292
  306
  320
  336
  352
  369
  387
  406
  426
  447
  469
  492
  516
  542
  569
Issuance/(repurchase) of shares, $m
  40
  10
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  193
  166
  163
  170
  178
  185
  194
  203
  212
  221
  232
  243
  254
  266
  279
  292
  306
  320
  336
  352
  369
  387
  406
  426
  447
  469
  492
  516
  542
  569
Total cash flow (excl. dividends), $m
  401
  405
  435
  476
  520
  567
  615
  667
  721
  778
  770
  833
  900
  970
  1,044
  1,122
  1,204
  1,291
  1,382
  1,479
  1,580
  1,688
  1,801
  1,920
  2,045
  2,178
  2,317
  2,464
  2,619
  2,783
Retained Cash Flow (-), $m
  -110
  -116
  -121
  -126
  -131
  -137
  -143
  -150
  -157
  -164
  -171
  -179
  -188
  -197
  -206
  -216
  -226
  -237
  -248
  -260
  -273
  -286
  -300
  -315
  -330
  -347
  -364
  -382
  -400
  -420
Prev. year cash balance distribution, $m
  692
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  983
  289
  314
  351
  389
  430
  472
  517
  564
  614
  599
  654
  712
  773
  838
  906
  978
  1,054
  1,134
  1,218
  1,307
  1,401
  1,500
  1,605
  1,715
  1,831
  1,954
  2,083
  2,219
  2,363
Discount rate, %
  4.50
  4.73
  4.96
  5.21
  5.47
  5.74
  6.03
  6.33
  6.65
  6.98
  7.33
  7.70
  8.08
  8.49
  8.91
  9.36
  9.82
  10.31
  10.83
  11.37
  11.94
  12.54
  13.16
  13.82
  14.51
  15.24
  16.00
  16.80
  17.64
  18.52
PV of cash for distribution, $m
  940
  264
  272
  286
  298
  307
  313
  316
  316
  313
  275
  269
  259
  247
  233
  217
  199
  180
  161
  141
  122
  104
  87
  72
  58
  46
  36
  27
  20
  14
Current shareholders' claim on cash, %
  99.3
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1
  99.1

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

FINANCIAL RATIOS  of  Qiagen (QGEN)

Valuation Ratios
P/E Ratio 97.4
Price to Sales 5.8
Price to Book 3
Price to Tangible Book
Price to Cash Flow 22.8
Price to Free Cash Flow 31.4
Growth Rates
Sales Growth Rate 4.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -19.7%
Cap. Spend. - 3 Yr. Gr. Rate -4.6%
Financial Strength
Quick Ratio 532
Current Ratio 0
LT Debt to Equity 40.9%
Total Debt to Equity 41%
Interest Coverage 4
Management Effectiveness
Return On Assets 2.5%
Ret/ On Assets - 3 Yr. Avg. 3.1%
Return On Total Capital 2.2%
Ret/ On T. Cap. - 3 Yr. Avg. 3%
Return On Equity 3.1%
Return On Equity - 3 Yr. Avg. 4.1%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 63.2%
Gross Margin - 3 Yr. Avg. 64.7%
EBITDA Margin 21.5%
EBITDA Margin - 3 Yr. Avg. 24.8%
Operating Margin 7.4%
Oper. Margin - 3 Yr. Avg. 11.1%
Pre-Tax Margin 4.3%
Pre-Tax Margin - 3 Yr. Avg. 7.9%
Net Profit Margin 6%
Net Profit Margin - 3 Yr. Avg. 8.3%
Effective Tax Rate -40.4%
Eff/ Tax Rate - 3 Yr. Avg. -11.4%
Payout Ratio 0%

QGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the QGEN stock intrinsic value calculation we used $1417.536 million for the last fiscal year's total revenue generated by Qiagen. The default revenue input number comes from 0001 income statement of Qiagen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our QGEN stock valuation model: a) initial revenue growth rate of 6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.5%, whose default value for QGEN is calculated based on our internal credit rating of Qiagen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Qiagen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of QGEN stock the variable cost ratio is equal to 31.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $840 million in the base year in the intrinsic value calculation for QGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Qiagen.

Corporate tax rate of 27% is the nominal tax rate for Qiagen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the QGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for QGEN are equal to 120.9%.

Life of production assets of 13.7 years is the average useful life of capital assets used in Qiagen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for QGEN is equal to 21.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2540.996 million for Qiagen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 226.557 million for Qiagen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Qiagen at the current share price and the inputted number of shares is $7.8 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 237.69 199.97  hold
TROV TrovaGene 0.770 0.09  str.sell
HOLX Hologic 41.34 27.04  sell
GNMK GenMark Diagno 4.74 0.31  str.sell
GHDX Genomic Health 78.89 51.74  hold
ILMN Illumina 319.51 182.51  sell

COMPANY NEWS

▶ Vanguard Health Care Fund Buys 4 Stocks in 3rd Quarter   [Nov-07-18 12:40PM  GuruFocus.com]
▶ QIAGEN Acquires Growth   [Nov-01-18 04:13PM  Motley Fool]
▶ Qiagen (QGEN) Q3 Earnings Surpass Estimates   [Oct-29-18 05:25PM  Zacks]
▶ Qiagen: 3Q Earnings Snapshot   [04:21PM  Associated Press]
▶ How Financially Strong Is QIAGEN NV (NYSE:QGEN)?   [Sep-27-18 01:38PM  Simply Wall St.]
▶ QIAGEN to Join Germanys MDAX Index in Addition to TecDAX   [Sep-12-18 04:00PM  Business Wire]
▶ QIAGEN NV to Host Earnings Call   [07:00AM  ACCESSWIRE]
▶ Qiagen: 2Q Earnings Snapshot   [05:04PM  Associated Press]
▶ IBD Rating Upgrades: Qiagen Flashes Improved Relative Price Strength   [May-24-18 03:00AM  Investor's Business Daily]
▶ Qiagen Starts Slowly but Is On Track   [May-07-18 05:52PM  Motley Fool]
▶ Qiagen: 1Q Earnings Snapshot   [May-02-18 07:19PM  Associated Press]
▶ QIAGEN Announces FDA Approval of PartoSureTM   [Apr-20-18 02:00AM  Business Wire]
▶ QIAGEN N.V. to Report First Quarter 2018 Results   [Apr-17-18 07:52AM  Business Wire]
▶ QIAGENs QuantiFERON-TB Gold Plus gains approval in Japan   [Feb-08-18 04:05PM  Business Wire]
▶ Qiagen reports 4Q loss   [05:02AM  Associated Press]
▶ Should You Buy QIAGEN NV (NYSE:QGEN) Now?   [07:09AM  Simply Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.